| Catalog No. | HP378016 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Functional assay, Research in vivo |
|---|
| Host species | Humanized |
|---|
| Isotype | Humanized IgG1-kappa anti-human TCR Vβ6/β10 monomer disulfide bridged to human IL-2 fragment fused via (G4S)2 peptide linker to immunoglobulin G1 Fc fragment. |
|---|
| Expression system | Mammalian Cells |
|---|
| Target | IL2, IL-2, Aldesleukin, Interleukin-2, TCGF, T-cell growth factor |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Accession | P60568 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Alternate Names | 2894138-60-2 |
|---|
| Background | HY-P990958 is an T cell receptor germline-encoded variable chain Vβ6/β10-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
• Aldesleukin (recombinant interleukin-2)., PMID:18031103
• High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014., PMID:31546315
• Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease., PMID:38319239
• Low-dose IL-2 enhances the generation of IL-10-producing immunoregulatory B cells., PMID:37045832
• Rethinking Oncologic Treatment Strategies with Interleukin-2., PMID:37174716
• Aldesleukin. Interleukin-2 (IL-2), IL-2 (Chiron), Macrolin, Proleukin, recombinant IL-2 (Chiron), T cell growth factor., PMID:10659407
• Aldesleukin (recombinant interleukin-2): a review of its pharmacological properties, clinical efficacy and tolerability in patients with renal cell carcinoma., PMID:18020488
• The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma., PMID:19692326
• Low-dose interleukin 2 antidepressant potentiation in unipolar and bipolar depression: Safety, efficacy, and immunological biomarkers., PMID:38367846
• Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus., PMID:26324847
|
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
